Performance of the Vitek 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales from North and Latin America.

This study evaluated the performance of the Vitek 2 Advanced Expert System (AES) confidence level report as a rapid tool for reporting antimicrobial susceptibility testing (AST) results for a challenging set of isolates from North and Latin America. isolates (=513) were tested by CLSI broth microdilution (BMD) and Vitek 2 (N802 and XN15 AST cards). Wild-type isolates and isolates harboring acquired β-lactamases by whole-genome sequencing were included. The AES assessment of confidence level (green, yellow, and red reports) was compared to BMD results and known genotypes and reviewed by a microbiologist for accuracy. Totals of 148 (28.8%) wild-type isolates and 365 (71.2%) isolates harboring carbapenemase (211 [41.1%]), extended-spectrum β-lactamase (ESBL) (122 [23.8%]), and/or transferrable AmpC (tAmpC) (32 [6.2%]) genes were evaluated. The AES confidence level was assessed for 488 isolates, and a phenotype was recognized for 447 (91.6%) isolates. Green, yellow, and red AES reports were noted for 382 (78.3%), 65 (13.3%), and 41 (8.4%) isolates, respectively. Compared to BMD, 96.3% of green AES reports could be confidently and rapidly auto-released, enabling rapid adjustments to antimicrobial therapy. In addition, 69.2% of yellow reports were acceptable, and recommendations to address current AES limitations were made. Antimicrobial susceptibility testing (AST) reports are one of the most important clinical microbiology laboratory tasks. AST reports are essential to drive antimicrobial therapy, provide information to monitor antimicrobial resistance rates, and trigger further tests to detect outbreaks or confirm new mechanisms of resistance. Commercial AST devices are frequently used to generate AST reports, and an advanced expert system (AES), such as the Vitek 2 AES, incorporates extensive knowledge to recognize certain susceptibility patterns as indicative of specific phenotypes. Moreover, the Vitek 2 AES also provides a level of confidence for auto-releasing the reports. In this study, the performance of the Vitek 2 AES was compared to state-of-the-art methodologies for AST, broth microdilution and β-lactamase gene detection, whole-genome sequencing, against a collection of 513 clinical isolates harboring various β-lactamase genes, including carbapenemase, ESBL, and transferrable AmpC genes, from 73 medical centers in 7 countries in North and Latin America.